Roche ter­mi­nates a Phase 3 Spark gene ther­a­py in he­mo­phil­ia A

Roche has of­fi­cial­ly dis­con­tin­ued a Phase 3 he­mo­phil­ia A gene ther­a­py from its Spark Ther­a­peu­tics unit, a spokesper­son for the Swiss phar­ma told End­points News …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER